Table 4.

Patient characteristics, VTE risk, and prophylaxis use between patients with and without VTE

In-hospital VTE (N = 36)No in-hospital VTE (N = 3985)P value
Median age (IQR), y 51 (35-67) 57 (43-69) .25 
Female, n (%) 23 (69.9) 2 000 (50.2) .13 
Race, n (%)   .82 
Black 17 (47.2) 2 071 (52.0)  
White 15 (41.7) 1 557 (39.1)  
Other 4 (11.1) 357 (9.0)  
Median BMI (IQR), kg/m2 26.6 (22.6-30.8) 26.6 (22.3-32.3) .67 
Median LOS (IQR), d 14.5 (8.5-26.5) 4 (3-8) <.001 
Median Padua score (IQR)    
Expert 5 (4-6) 2 (1-4) <.001 
Prescriber 1 (0-3) 1 (0-3) .61 
Patients VTE risk level, n (%)   <.001 
Discordant high 21 (58.3) 1 135 (28.5)  
Discordant low 0 (0) 240 (6.0)  
Concordant high 11 (30.6) 807 (20.3)  
Concordant low 4 (11.1) 1803 (45.2)  
Patients prescribed any prophylaxis during hospitalization, n (%) 31 (86.1) 2293 (57.5) <.001 
Number of doses prescribed 504 23 513  
Doses given, n (%) 405 (80.4) 19 945 (84.8) .007 
Doses missed, n (%) 14 (2.8) 779 (3.3) .62 
Doses refused, n (%) 85 (16.9) 2 789 (11.9) .001 
In-hospital VTE (N = 36)No in-hospital VTE (N = 3985)P value
Median age (IQR), y 51 (35-67) 57 (43-69) .25 
Female, n (%) 23 (69.9) 2 000 (50.2) .13 
Race, n (%)   .82 
Black 17 (47.2) 2 071 (52.0)  
White 15 (41.7) 1 557 (39.1)  
Other 4 (11.1) 357 (9.0)  
Median BMI (IQR), kg/m2 26.6 (22.6-30.8) 26.6 (22.3-32.3) .67 
Median LOS (IQR), d 14.5 (8.5-26.5) 4 (3-8) <.001 
Median Padua score (IQR)    
Expert 5 (4-6) 2 (1-4) <.001 
Prescriber 1 (0-3) 1 (0-3) .61 
Patients VTE risk level, n (%)   <.001 
Discordant high 21 (58.3) 1 135 (28.5)  
Discordant low 0 (0) 240 (6.0)  
Concordant high 11 (30.6) 807 (20.3)  
Concordant low 4 (11.1) 1803 (45.2)  
Patients prescribed any prophylaxis during hospitalization, n (%) 31 (86.1) 2293 (57.5) <.001 
Number of doses prescribed 504 23 513  
Doses given, n (%) 405 (80.4) 19 945 (84.8) .007 
Doses missed, n (%) 14 (2.8) 779 (3.3) .62 
Doses refused, n (%) 85 (16.9) 2 789 (11.9) .001 

or Create an Account

Close Modal
Close Modal